For Grants and Contracts

NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this publication ☐ Check here if your address has changed and you wish to continue receiving this publication. Make corrections below and mail this page to: NIH Guide Distribution Center National Institutes of Health Room B3BE07, Building 31 Bethesda, Maryland 20892

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

OFFICIAL BUSINESS
Penalty for Private Use, \$300

The NiH Guide announces scientific initiatives and provides policy and administrative information to individuals and organizations who need to be kept informed of opportunities, requirements, and changes in extramural programs administered by the National Institutes of Health.

Third-Class Mail Postage & Fees Paid PHS/NIH/OD Permit No. G-291

NOTICES

NURSING RESEARCH RELATED TO AIDS1 National Center for Nursing Research Index: NURSING RESEARCH
CONFERENCES ON ANIMAL CARE AND USE COMMITTEES AND RESEARCH WITH SPECIAL POPULATIONS1 Public Responsibility in Medicine and Research (PRIM&R) Index ANIMALS HUMAN SUBJECTS
SPECIAL RECEIPT DATE FOR CERTAIN NIMH PROGRAMS
INCLUSION OF WOMEN IN STUDY POPULATIONS
DATED ANNOUNCEMENTS (RFPs and RFAs AVAILABLE)
REQUEST FOR COOPERATIVE AGREEMENT APPLICATIONS IN RECRUITMENT AND ENROLLMENT IN CLINICAL TRIALS
INTERNATIONAL COLLABORATION IN ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH
ONGOING PROGRAM ANNOUNCEMENTS
DIETARY AND NUTRITIONAL FACTORS IN DRUG ABUSE
RESEARCH INTO METHODS OF RESEARCH THAT DO NOT USE VERTEBRATE ANIMALS, USE FEWER VERTEBRATE ANIMALS, OR PRODUCE LESS PAIN AND DISTRESS IN VERTEBRATE ANIMALS USED IN RESEARCH

NOTICES

NURSING RESEARCH RELATED TO AIDS

P.T. 34; K.W. 0715120, 0785130, 0755030, 0730060, 0783010, 0730070

National Center for Nursing Research

The National Center for Nursing Research (NCNR) has identified nursing research activities related to AIDS as a priority program area compatible with the Center's mission. Investigators should focus on research designed to enhance AIDS prevention and to improve mechanisms for providing nursing care to acute and long-term AIDS patients. Topics of primary interest include, but are not limited to, the following:

Etiology of AIDS including identification of predictive factors; nursing care of AIDS patients at various stages of the disease, comparative therapeutic and cost effectiveness of nursing interventions in the home, nursing homes and institutional settings; knowledge, attitudes, practices of AIDS patients and effect of AIDS on family functioning; ethical issues related to diagnosis and treatment strategies; public policy issues such as methods of early screening and diagnosis and control of the spread of the disease and integration of patients, including infants and young children, in community settings.

For further information contact:

National Center for Nursing Research Building 38A, Room B2E17 National Institutes of Health Bethesda, Maryland 20894 Telephone: (301) 496-0526

CONFERENCES ON ANIMAL CARE AND USE COMMITTEES AND RESEARCH WITH SPECIAL POPULATIONS

P.T. 42; K.W. 0201011, 1014003, 0783005

Public Responsibility in Medicine and Research (PRIM&R)

Public Responsibility in Medicine and Research (PRIM&R) is sponsoring two conferences this spring in Boston, the first on animal care and use committees, and the second on research with special populations.

"Making Your Animal Care Committee Work: Current Issues and Practical Problems" will be held on March 16-17 at the Copley Plaza Hotel. The meeting will focus on issues affecting Institutional Animal Care and Use Committees (IACUCs), ranging from the practical problems of establishing and maintaining a committee, to specific scientific techniques and the ethical issues surrounding research with animals.

The second meeting, "Research with Special Populations: Ethical and Legal Issues, Determining Competence, Obtaining Consent, and Institutional Policy Development" will be held on April 27-28 at the Boston Park Plaza Hotel. The conference will address the issues of the mentally ill, children, the elderly, AIDS patients, and others. For more information, and a complete program, please contact:

Joan Rachlin or Nadine Dolby PRIM&R 132 Boylston Street Boston, Massachusetts 02116 Telephone: (617) 423-4112 or 1099

SPECIAL RECEIPT DATE FOR CERTAIN NIMH PROGRAMS

P.T. 22, 34; K.W. 0715095, 0720005, 0404000, 0414000, 0710030

National Institute of Mental Health

As part of its major emphasis on schizophrenia research, the National Institute of Mental Health (NIMH) has established a special one-time receipt date of March 16, 1987, for the following research manpower development programs: Individual Research Training Fellowships, Small Grants, Research Scientist Development Awards (RSDAs), Physician Scientist Awards, Clinical Investigator Awards, and First Independent Research Support and Transition(FIRST) Awards. NIMH will also accept schizophrenia

research and research training applications on the regular receipt dates. NIMH program staff will provide specific information and consultation about these programs. For further information, please call: (301) 443-4707

INCLUSION OF WOMEN IN STUDY POPULATIONS

P.T. 34; K.W. 0770000, 1014002

National Institutes of Health Alcohol, Drug Abuse, and Mental Health Administration

The Public Health Service Task Force on Women's Health Issues published its report in the January 1985 issue of Public Health Reports. One of the Task Force's major recommendations was that biomedical and behavioral research be expanded to assure appropriate emphasis on conditions and diseases unique to, or more prevalent in, women of all age groups.

In keeping with one aspect of this recommendation, the NIH and the ADAMHA urge applicants for grants and offerors for contracts to consider the inclusion of women in the study populations for all clinical research efforts. Exceptions would be studies of diseases which exclusively affect males or where involvement of pregnant women may expose the fetus to undue risks. General differences should be noted and evaluated. If women are not to be included, a clear rationale should be provided for their exclusion.

In order to provide more precise information to the medical community, it is recommended that publications resulting from NIH or ADAMHA-supported research in which the study population was limited to one sex for any reason other than that the disease or condition studied exclusively affects that sex, should state, in the abstract or summary, the gender of the population studied, e.g., "male patients," "male volunteers," "female patients," "female volunteers."

For further clarification or discussion of this issue, contact:

National Institutes of Health Luz A. Froehlich, M.D. Chairperson, NIH Advisory Committee on Women's Health Issues Telephone: (301) 496-7688

Alcohol, Drug Abuse, and Mental Health Administration Delores L. Parron, Ph.D.
Associate Director for Special Populations, NIMH Coordinator for Special Populations, ADAMHA Telephone: (301) 443-2847

DATED ANNOUNCEMENTS (RFPs and RFAs AVAILABLE)

REQUEST FOR COOPERATIVE AGREEMENT APPLICATIONS IN RECRUITMENT AND ENROLLMENT IN CLINICAL TRIALS

RFA AVAILABLE: 87-HL-09-P

P.T. 34; K.W. 0755015, 0414014, 0403017, 0404021

National Heart, Lung, and Blood Institute

Application receipt date: April 15, 1987

The Clinical Trials Branch of the Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute (NHLBI) announces the availability of a Request for Cooperative Agreement Applications (RFA) on the above subject. Copies of the RFA are currently available from staff of the NHLBI.

This program will support research to identify characteristics of patients and organizations associated with inadequate participant enrollment, including refusal problems, in clinical trials. Researchers may study the identification, recruitment and enrollment of eligible participants and compare the demographic, psychosocial, and morbidity characteristics of participants with those of eligible nonparticipants. In addition, characteristics of the recruitment system which may influence the identification and enrollment of eligible individual will be studied.



This RFA may be of interest to nurse researchers. The Principal Investigator or other members of the research team should have clinical and research experience in the cardiovascular diseases field and a knowledge of the principles of multicenter clinical trials. There is an opportunity to conduct research within an existing clinical trial. Currently, the NHLBI is supporting the Cardiac Arrhythmia Suppression Trial (CAST), a multicenter clinical trial of antiarrhythmic therapy on post-myocardial infarction patients with ventricular arrhythmia. The recruitment phase begins during 1987, consequently this population will soon be available for study of the issues addressed in this RFA. Applicants must demonstrate the capability for establishing a working relationship with clinical center staff of the CAST or a similar clinical trial from which they would recruit patients.

Requests for copies of this RFA should be addressed to:

Eleanor Schron, R.N., M.S. Federal Building, Room 604 Clinical Trials Branch Division of Eidemiology and Clinical Applications National Institutes of Health Bethesda, Maryland 20892 Telephone: (301) 496-3107

INTERNATIONAL COLLABORATION IN ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESEARCH

RFA AVAILABLE: 87-AI-10

P.T. 34; K.W. 0715120, 0785055, 0411005, 1002045, 0403020

National Institute of Allergy and Infectious Diseases

Letter of Intent Receipt Date: April 15, 1987 Application Receipt Date: September 15, 1987



The AIDS Program of the National Institute of Allergy and Infectious Diseases invites the submission of Program Project Grant applications to establish a program in International Collaboration in AIDS Research. The program objective is a collaborative effort between a U.S. laboratories and those of host countries in biomedical research of recognized relevance to the health of people in those foreign countries. The AIDS Program is interested in research on HTLV-III/LAV and related diseases. This infection constitutes a major world problem and is of mutual concern to the World Health Organization. The Institute has a broad interest in the virology, immunology, pathogenesis, epidemiology, diagnosis, treatment, control and prevention of HTLV-III/LAV infection. Of special programmatic interest are perinatal and pediatric infection and heterosexual transmission; variability in viral isolates in different geographic areas and correlation with clinical and epidemiologic factors; potential role of co-factors; and similarities and differences in clinical and epidemiologic presentation of disease in different geographical areas.

The grant will be awarded to a United States based institution which has developed a satisfactory affiliation with an established university, research institute, federal or state health department, or the equivalent thereof, in the foreign host country. It is projected that 70-80 per cent of the research will be done in the host country.

APPLICATION PROCEDURES

Prospective applicants are advised to request a brochure entitled: Information Brochure: The Program Project Grant (NIAID) which details instructions on the requisites of a program project, the review criteria, and how to prepare the application. This brochure should be requested from:

Executive Secretary for Special Reviews (AIDS) Program and Project Review Branch Extramural Activities Program NIAID, National Institutes of Health Room 703, Westwood Building Bethesda, Maryland 20892 Telephone: (301) 496-0123

In response to this RFA, prospective applicants are requested to submit a letter of intent for program information on or before April 15, 1987. The letter of intent is not binding nor is it a requisite for the submission of a grant application. The letter should be sent to Dr. Harold Ginzburg at the address shown below.

INQUIRIES

Copies of the RFA and additional information may be obtained from:

Harold M. Ginzburg, MD, JD, MPH
Chief, Epidemiology Branch
AIDS Program
National Institute of Allergy and Infectious Diseases
Westwood Building, Room 753
5333 Westbard Avenue
Bethesda, Maryland 20892
Telephone: (301) 496-6177

ONGOING PROGRAM ANNOUNCEMENTS

DIETARY AND NUTRITIONAL FACTORS IN DRUG ABUSE

DA-87-07

P.T. 34; K.W. 0404009, 0710095, 0710100, 0404001

National Institute on Drug Abuse

Application Receipt Dates: June 1, October 1, February 1

INTRODUCTION

The National Institute on Drug Abuse (NIDA) makes grant awards for basic and applied research projects. Grant support is available to develop knowledge in a wide range of areas related to drug abuse. During the past decade numerous studies have demonstrated that nutritional status affects the physiological and metabolic processes of the CNS in many important ways. Recently limited evidence has been published which indicates clearly that food deprivation and some nutritional factors can modify not only a pharmacological response to opiates, e.g., analgesia, but also influence the withdrawal syndrome as well as the self-administration of drugs. Food deprivation is known to increase the i.v. or p.o. self-administration of several drugs, e.g., etonitazine, cocaine, PCP and ethanol. On the other hand, 1-tryptophan (an essential amino acid) pretreatment of animals at doses which are known to increase brain serotonin, has been reported to reduce i.v. self-administration of amphetamine. Glucose has been demonstrated to influence the development of tolerance to the analgesic effect of morphine whereas palatability of food can also have an important effect on subsequent food selection as well as pain sensitivity. These findings, although preliminary, are very exciting and if confirmed raise the possibility of eventually influencing human drug seeking behavior through dietary manipulation. However, some fundamental knowledge regarding the role of nutrients and dietary factors in the development of tolerance and physical dependence needs to be developed before we can begin to understand the role of diet and nutrition in drug seeking behavior.

Although the research on the role of dietary factors on drug abuse processes is still at an early stage of exploration, this area is of direct interest to the immediate and long range research goals of the NIDA. An expanded research program is planned based partly on this announcement to encourage and stimulate research on the role of dietary, nutritional, and environmental factors on the pharmacology of tolerance to and physical dependence on drugs of abuse.

Applications received in response to the announcement will be assigned for review and funding consideraton in accordance with established Public Health Service (PHS) guidelines. Grant awards are made under the authority of Section 301 of the Public Health Service Act, as amended (42 USC 241). Federal regulations at 42 CFR Part 52, "Grants for Research Projects" apply to grants under this announcement. This program is not subject to the intergovernmental review requirements of Executive Order 12372 as implemented through HHS regulations at 45 CFR Part 100.

AREAS OF INTEREST

The determination of what macro or micro nutrients influence or modulate pharmacological responses to drugs of abuse, development of tolerance, physical dependence, self-administration of drugs or other compulsive behavior will be of general interest to NIDA. Studies of mechanisms whereby the above behaviors may be modulated would be particularly important. Hence grant applications are solicited in the following specific areas:

Studies related to: the influence of macro or micro nutrients or dietary components on the pharmacological responses to drugs of abuse including the course of development of tolerance and physical dependence as well as patterns of self-administration of drugs, and establishing causal relationships or covariances among these responses; the modulation of other compulsive behaviors, e.g., compulsive eating, by dietary constituents; and the effects of palatability of foods on drug seeking behavior; the involvement of opicid peptides and opiate receptors in the modulation of ingestive behavior and obesity; the effects of drugs of abuse on ingestive behavior; the involvement of endogenous opiatergic mechanisms in taste and food preference; the effects of nutritional and dietary factors on disposition and metabolism of drugs of abuse.

Studies on the effects of dietary factors on autonomic nervous system (adrenergic/cholinergic function) and correlation of alteration of this function with tolerance development, or physical dependence or ingestive behavior.

Studies on the effects of environmental factors, related to nutritional status, and the development of tolerance and physical dependence. Research may include the studies of hibernation, seasonal variations and climatic conditions (temperature), etc. which are relatable to nutritional status, as they influence the development of physical dependence.

Studies on obesity dealing with correlations and interactions between metabolic parameters, patterns of food ingestion and consumption of psychoactive drugs. Changes in the effects of behaviorally active drugs as a function of weight loss and weight gain. Studies on specific patterns of drug use as a function of nutritional disorder. Studies on the development of obesity either as an antecedent or consequence of drug use, the relationship between eating disorders and other stereotypic disorders including drug use and relationship between mood states, food intake and drug use.

ELIGIBILITY

Applications for drug abuse research grants may be made by public or private nonprofit or profit-making organizations such as universities, colleges, hospitals, laboratories, research institutes and organizations, units of State or local governments, and eligible Federal institutions. NIDA is interested in receiving applications from well-qualified individuals; women and minority candidates, in particular, are encouraged to apply.

APPLICATION PROCEDURES

The standard research grant application form PHS 398 (revised 5/82) must be used to apply for these awards. When applying, type the name of this announcement "Dietary and Nutritional Factors in Drug Abuse" on page 1, item 2 of PHS 398. State and local agencies should use form PHS 5161 (revised 3/86).

Application kits containing the necessary forms and instructions (PHS 398) may be obtained from institutional business offices or offices of sponsored research at most universities, colleges, medical schools, and other major research facilities. Application forms may also be obtained from:

Grants Management Branch National Institute on Drug Abuse 5600 Fishers Lane, Room 10-25 Rockville, Maryland 20857 Telephone (301) 443-6710

The signed original and six permanent legible copies (two copies if using form PHS 5161) of the completed application should be submitted to:

Division of Research Grants, NIH Westwood Building 5333 Westbard Avenue Bethesda, Maryland 20892

STAFF CONTACT

The guidelines, other information about the drug abuse research grants program, and further information about areas of interest described in this announcement may be obtained by contacting:

Khursheed Asghar, Ph.D.
Biomedical Branch, Division of Preclinical Research,
National Institute on Drug Abuse,
5600 Fishers Lane, Room 10A-31,
Rockville, Maryland 20857
Telephone (301) 443-6300

REVIEW PROCEDURE AND SCHEDULE OF RECEIPT DATES AND REVIEW

Applications received under this announcement will be reviewed for scientific and technical merit by an Initial Review Group (IRG) consisting primarily of non-Federal technical and scientific experts.

Applications are also subject to review by the National Advisory Council on Drug Abuse, which will make final recommendations to the Director, NIDA. Notification of review outcome will be sent to the applicant by the NIDA. Only applications recommended for approval by the NIDA Advisory Council will be considered for funding.

The rotating submission dates and schedule of review are:

Receipt of Application	Initial Review Group	Advisory Council Review	Earliest Award Date
June 1	October	January/February	April 1
October 1	February	May/June	July 1
February 1	June	September/October	December 1

REVIEW CRITERIA

Criteria to be used in the merit review of research grant applications include the following:

- 1 The overall scientific and technical merit of the proposal, including the significance and originality of the goals from a scientific standpoint and the adequacy of the methodology to carry out the proposed research.
- 2 Adequacy of design for collection and analysis of the data, including research schematics, detailed analysis plans, and proposed instrumentations.
- 3 The adequacy of the qualifications (including level of education, training, and research experience) of the Principal Investigator and key research personnel.
- 4 The quality of the applicant's past and present research performance as related to the proposed project.
- 5 Availability of adequate facilities and equipment, general environment for the conduct of the proposed research, other resources, and appropriateness of collaborative arrangements.
- 6 The appropriateness of budget estimates for the proposed research activities.
- 7 Where applicable, adequacy of procedures to protect or minimize effects on human subjects and to assure humane care and use of laboratory animals.

TERMS AND CONDITIONS OF SUPPORT

Grant funds may be used for expenses clearly related and necessary to carry out research projects, including both direct costs which can be specifically identified with the project and allowable indirect costs of the institution. Research grant support is not provided to establish, add a component to, or operate a prevention, intervention, or treatment program. support for research-related costs of projects may be requested only for those particular costs and for that period of time required by the research. Such costs must be justified in terms of research objectives, methods, and design which promise to yield important generalized

knowledge and/or make a significant contribution to theoretical concepts. Grants will be administered in accordance with the PHS Grants Policy Statement. In addition, the applicant should be aware that portions of the regulations on Confidentiality of Alcohol and Drug Abuse Patient Records, 42 CFR 2, may be relevant and applicable.

AWARD CRITERIA AND AVAILABILITY OF FUNDS

Applications recommended for approval by the National Advisory Council on Drug Abuse will be considered for funding on the basis of overall scientific and technical merit of the proposal as determined by peer review. Applications received under this announcement will compete with others submitted to the NIDA. Priority will be given to funding research grant applications in response to this announcement in FY 1987 and future years. However, there are no specific set-aside funds for this area.

PERIOD OF SUPPORT

Up to 5 years of support is available. Support beyond that period must be requested by a competing renewal application which will undergo the dual review process described above and, if recommended for approval, will compete for available funds.

Catalogue of Federal Domestic Assistance No. 13.279

RESEARCH INTO METHODS OF RESEARCH THAT DO NOT USE VERTEBRATE ANIMALS, USE FEWER VERTEBRATE ANIMALS, OR PRODUCE LESS PAIN AND DISTRESS IN VERTEBRATE ANIMALS USED IN RESEARCH

P.T. 34; K.W. 0755020, 0710030, 1002027, 0780015, 0780020

National Institutes of Health

Application Receipt Dates: February 1, June 1, October 1

BACKGROUND

As part of the plan for research into research methods that do not use animals, use fewer animals, or produce less pain and distress in animals used in research, called for in NIH's authorizing legislation, P.L. 99-158, Section 4, the National Institutes of Health invites grant applications for the support of development and validation of research methods promoting these objectives.

Biomedical research cannot be regarded separately from biological research. Applications of basic biology to clinical medicine are often apparent, but cannot, in general, be predicted. Some proposals—for the study of invertebrates, lower vertebrates, microorganisms, cell and tissue culture systems, or mathematical approaches—can be regarded as having the same potential relevance to biomedical research as proposals for work on systems that are phylogenetically more closely related to humans. Experience indicates that information yielded by such systems can contribute substantially to increasing knowledge of human function.

While it is recognized that animals have been and will continue to be essential to the advancement of knowledge in the biomedical sciences, non-animal research methods can and do provide additional opportunities to advance our understanding of basic mechanisms of fundamental biological processes. For example, biological models or model systems derived from or consisting of nonmammalian organisms, or cell and tissue culture systems, may serve to reduce the use of mammals in the early stages of some investigations and may provide insights into mechanisms of biological functions that are more difficult to obtain from studies of whole vertebrate animals. Non-invasive experimental techniques, permitting studies of biological processes in intact animals, can reduce the number of animals needed as multi-step phenomena can be observed within a single subject. Such technologies often permit studies impossible to perform otherwise. Mathematical modeling is another useful investigational strategy when closely coupled to biological experimentation, and there are opportunities for mathematical modeling in many areas of biomedical research.

RESEARCH GOALS

Grant applications are requested for projects that will increase the extent and depth of knowledge needed to develop methods of biomedical research and experimentation that:

- do not require the use of vertebrate animals
- reduce the number of vertebrate animals used in research produce less pain and distress in vertebrate animals than methods currently used
- validate or demonstrate the reliability of non-animal methods
- develop non-vertebrate animal research methods that have been found valid and reliable.

MECHANISM OF SUPPORT

The support mechanism for this program will be the traditional investigator-initiated research project grant. Under this mechanism, the applicant will plan, direct, and carry out the research program. The project period during which the research will be conducted should adequately reflect the time required to accomplish the stated goals and be consistent with the policy for grant support. Support will be provided for up to five years (renewable for subsequent periods) subject to the availability of funds and progress achieved.

Research grant applications may be submitted by both nonprofit and profit-making organizations and institutions, State or local governments and their agencies, and eligible agencies of the Federal Government.

APPLICATIONS AND REVIEW PROCEDURES

Applications in response to this solicitation will be appropriately peer reviewed for scientific and technical merit. They will be judged on the overall scientific merit of the proposed research, potential significance of the research findings, adequacy of methodology, availability of necessary facilities, and the qualifications of the research team. A secondary review for policy and program relevance to the research needs and missions of the Bureau, Institute, or Division to which the proposal is assigned will be made by the respective National Advisory Councils

Applications will be received by the NIH Division of Research Grants on PHS Form 398, "Application for Public Health Service Grant," in accordance with the usual receipt dates for new applications:

February 1

June 1

October 1

FOR FURTHER INFORMATION CONTACT:

Division of Research Resources Dr. James D. Willett Chief, Biomedical Models and Materials Resources Section Animal Resources Program Building 31, Room 5B23 Bethesda, Maryland 20892 Telephone: (301) 496-5175

National Cancer Institute Dr. Michael Boyd Associate Director for Developmental Therapeutics Landow Building, Room 5A21B Bethesda, Maryland 20892 Telephone: (301) 496-8720

National Center for Nursing Research Dr. Eileen Hasselmyer Special Assistant to Acting Director Building 38A, Room 2E17 Bethesda, Maryland 20892 Telephone: (301) 496-0523

National Eye Institute Dr. Michael D. Oberdorfer Director, Amblyopia and Visual Processing Program Building 31, Room 6A47
National Institutes of Health
Bethesda, Maryland 20892
Telephone: (301) 496-5301

National Institute of Allergy and Infectious Diseases Dr. Luz A. Froehlich Deputy Director, Extramural Activities Program Westwood Building, Room 703 Bethesda, Maryland 20892 Telephone: (301) 496-7688

National Institute on Aging Dr. Dewitt Hazzard Head, Resource Development, Biomedical Research and Clinical Medicine Building 31, Room 5C19 Bethesda, Maryland 20892 Telephone: (301) 496-6402

National Institute of Arthritis and Musculoskeletal and Skin Diseases Dr. Steven J. Hausman
Deputy Director, Extramural Activities Program
Westwood Building, Room 403
Bethesda, Maryland 20892
Telephone: (301) 496-7495

National Institute of Child Health and Human Development Dr. Antonia Novello Deputy Director Building 31, Room 2A04 Bethesda, Maryland 20892 Telephone: (301) 496-1848

National Institute of Diabetes and Digestive and Kidney Diseases Dr. Walter Stolz
Director, Division of Extramural Activities
Westwood Building, Room 657
Bethesda, Maryland 20892
Telephone: (301) 496-7277

National Institute of Dental Research Dr. Marie U. Nylen Associate Director for Extramural Program Westwood Building, Room 503 Bethesda, Maryland 20892 Telephone: (301) 496-7723

NEW YEAR

National Institute of Environmental Health Sciences Dr. Anne P. Sassaman Associate Director, Extramural Program Building 3, Room 301 P.O. Box 12233 Research Triangle Park, North Carolina 27709 Telephone: (919) 541-7723 or (FTS Number) 8-629-7723

National Institute of General Medical Sciences Dr. David Wolff Deputy Associate Director for Program Activities Westwood Building, Room 955 Bethesda, Maryland 20892 Telephone: (301) 496-7063

National Heart, Lung, and Blood Institute Dr. Henry G. Roscoe Westwood Building, Room 7A17A National Institutes of Health Bethesda, Maryland 20892 Telephone: (301) 496-7225

National Institute of Neurological and Communicative Disorders and Stroke Dr. Eugene Streicher Director, Fundamental Neurosciences Program Federal Building, Room 916 Bethesda, Maryland 20892 Telephone: (301) 496-5745